Last reviewed · How we verify
ketotifen fumarate 0.025% eye drops
ketotifen fumarate 0.025% eye drops is a Antihistamine Small molecule drug developed by Campus Bio-Medico University. It is currently in Phase 3 development for Allergic conjunctivitis. Also known as: Zaditen collirio monodose.
Ketotifen fumarate is an antihistamine that works by blocking histamine receptors in the eye.
Ketotifen fumarate is an antihistamine that works by blocking histamine receptors in the eye. Used for Allergic conjunctivitis.
At a glance
| Generic name | ketotifen fumarate 0.025% eye drops |
|---|---|
| Also known as | Zaditen collirio monodose |
| Sponsor | Campus Bio-Medico University |
| Drug class | Antihistamine |
| Target | Histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
By blocking histamine receptors, ketotifen fumarate reduces the allergic response and inflammation in the eye, providing relief from itching, redness, and tearing associated with allergic conjunctivitis.
Approved indications
- Allergic conjunctivitis
Common side effects
- Eye irritation
Key clinical trials
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis (PHASE3)
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. (PHASE3)
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. (PHASE3)
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. (PHASE3)
- Safety and Comfort of AL-4943A Ophthalmic Solution (PHASE1)
- Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketotifen fumarate 0.025% eye drops CI brief — competitive landscape report
- ketotifen fumarate 0.025% eye drops updates RSS · CI watch RSS
- Campus Bio-Medico University portfolio CI
Frequently asked questions about ketotifen fumarate 0.025% eye drops
What is ketotifen fumarate 0.025% eye drops?
How does ketotifen fumarate 0.025% eye drops work?
What is ketotifen fumarate 0.025% eye drops used for?
Who makes ketotifen fumarate 0.025% eye drops?
Is ketotifen fumarate 0.025% eye drops also known as anything else?
What drug class is ketotifen fumarate 0.025% eye drops in?
What development phase is ketotifen fumarate 0.025% eye drops in?
What are the side effects of ketotifen fumarate 0.025% eye drops?
What does ketotifen fumarate 0.025% eye drops target?
Related
- Drug class: All Antihistamine drugs
- Target: All drugs targeting Histamine receptor
- Manufacturer: Campus Bio-Medico University — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Allergic conjunctivitis
- Also known as: Zaditen collirio monodose
- Compare: ketotifen fumarate 0.025% eye drops vs similar drugs
- Pricing: ketotifen fumarate 0.025% eye drops cost, discount & access